Interleukin-6 (IL-6) is an inflammatory cytokine with diverse functions including regulation of the humoral and cellular immune response and induction of thrombopoiesis. It is presently under development as a therapeutic agent for induction of platelets following chemotherapy. Because IL-6 is a growth factor for some hematopoietic tumors (e.g., multiple myeloma), clinical protocols designed to regulate the synthesis or activity of IL-6 are also being investigated. The goal of the present work is to elucidate the mechanisms whereby IL-6 levels are regulated in vivo. We have developed a murine pre-clinical model for this purpose. The experimental system involves injection of the mineral oil pristane into the peritoneal cavities of BALB/c mice. This treatment induces a chronic peritonitis that is accompanied by dramatically elevated levels of intraperitoneal IL-6 as determined by bioassay and ELISA. Previous studies showed that the elevation in IL-6 can be inhibited by co-administration of the cyclooxygenase inhibitor indomethacin to the mice. We have found that the pristane-induced increase in IL-6 is associated with an elevation in endogenous prostaglandin E2 levels. The results suggest that prostaglandins secreted by inflammatory macrophages might be responsible for stimulating IL-6 production in the same cells through a positive feedback loop. A similar mechanism may contribute to the pathogenesis of human diseases in which both prostaglandins and IL-6 are chronically elevated (e.g., rheumatoid arthritis, Crohn's disease). Our recent data indicate that the source of the PGE2 may be critical in determining whether IL-6 synthesis is turned on or not. That is, when peritoneal macrophages are stimulated to synthesize PGE2 through prostaglandin synthase-1, which is expressed constitutively, little or no IL-6 synthesis is observed. However, when the same macrophages are stimulated to generate PGE2 through induction of prostaglandin synthase-2, IL-6 synthesis is turned on. Current studies are aimed at understanding the cellular mechanisms underlying this phenomenon.

Agency
National Institute of Health (NIH)
Institute
Food and Drug Administration (FDA)
Type
Intramural Research (Z01)
Project #
1Z01BN002011-03
Application #
2569002
Study Section
Special Emphasis Panel (LIM)
Project Start
Project End
Budget Start
Budget End
Support Year
3
Fiscal Year
1996
Total Cost
Indirect Cost